Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Illumina, Inc., a San Diego, California-headquartered biotechnology firm, announced that its chief financial officer, Joydeep Goswani, is leaving. His departure was confirmed on Tuesday, April 9.
New Executives at the HQ
The company said it has appointed Ankur Dhingra as its new CFO. Goswani's successor is revealed to be an executive at Summit Therapeutics. He will be leaving the company, where he most recently served in the same chief financial role, to join Illumina.
Aside from Dhingra, Illumina is also welcoming Jakob Wedel, who has been named the new chief strategy and corporate development officer. At any rate, Reuters reported that the new CFO worked at CareDx, a medical test manufacturer, before being hired at Summit Therapeutics. He also spent almost 18 years at Agilent Technologies and has decades of experience in the life science business sector.
Relocation and Date of Leadership Appointments
Meanwhile, Illumina's newly appointed senior executives, Dhingra and Wedel, are set to be transferred to San Diego for their respective roles. The two will start working at the company on April 15. On the other hand, Goswami will remain in the company until June 30 and officially leave on July 1.
"I am proud of the talent joining our management team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," Illumina's chief executive officer, Jacob Thaysen, said in a press release. "Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina's CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms."
The CEO added, "We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions. Joydeep will continue with us for several weeks to support a smooth leadership transition."
Photo by: Illumina Press Release
